Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
KPTIthis companyKaryopharm Therapeutics Inc.	$0.04	-0.41×	-0.27×	0.55×	-1.69×	-58773.0%	95.9%	-62.1%	-134.2%	66.9%	-236.6%	-93.6%	-0.8×	-1.15×	-1.98×	1.12×	0.0%	2	-27.45	2	B-
ALGSAligos Therapeutics, Inc.	$4.54	-3.8×	1.72×	42.14×	-3.45×	-97.4%	57.5%	-4024.9%	-1106.7%	-45.2%	-123.9%	-90.0%	0.1×	0.57×	0×	3.9×	0.0%	2	-16.11	2	C
CVMCEL-SCI Corporation	$1.49	-1.47×	2.34×	0×	-1.71×	-84.4%	0.0%	0.0%	0.0%	-159.2%	-97.4%	-46.0%	0.59×	0.08×	-38.23×	2.26×	0.0%	2	-38.36	2	C
INMBINmune Bio, Inc.	$1.14	-0.84×	1.76×	829.46×	-0.39×	-44.6%	100.0%	-61738.0%	-91866.0%	-195.3%	-125.7%	-57.0%	0.04×	0.52×	0×	3.55×	0.0%	1	-9.17	2	C+
SNTISenti Biosciences, Inc.	$0.16	-0.38×	41.84×	10,628.51×	-4.26×	-132.5%	-16431.8%	-289668.2%	-279263.6%	-1099.3%	-149.7%	-18.7%	5.17×	-0.22×	0×	1.67×	0.0%	2	-20.88	2	C
TELOTelomir Pharmaceuticals, Inc. Common Stock	$0.70	-4.03×	7.12×	0×	-3.39×	-78.2%	0.0%	0.0%	0.0%	-176.1%	-165.0%	-8.8%	0.08×	0.65×	0×	5.14×	0.0%	2	107.7	1	C-
Peer median	—	-1.47×	2.34×	42.14×	-3.39×	-84.4%	0.0%	-4024.9%	-1106.7%	-176.1%	-125.7%	-46.0%	0.1×	0.52×	0×	3.55×	0.0%	2	-16.11	2	—